ViroPharma Extends Buccolam's Reach - Analyst Blog


Shutterstock photo

ViroPharma Inc. ( VPHM ) recently announced that the Scottish regulatory body has approved its epilepsy drug, Buccolam to be used as a treatment for prolonged, acute, convulsive seizures in infants, toddlers, children and adolescents, aged 3 months to less than 18 years.

Earlier, in December last year, ViroPharma had announced the launch of Buccolam, in the United Kingdom for the same indication. In September 2011, the European Commission had granted Buccolam a Centralized Pediatric Use Marketing Authorization (PUMA) for the said indication.

PUMA is a new type of centralized marketing authorization procedure for medicines that are already authorized, but are no longer covered by intellectual property rights. Also, PUMA-authorized drugs are exclusively developed for children.

Buccolam became a part of ViroPharma's portfolio following the acquisition of Auralis Limited in May 2010.

We note that ViroPharma was in the news earlier this month when the US Food and Drug Administration (FDA) issued a complete response letter ( CRL ) for Cinryze's industrial scale manufacturing facility.

The regulatory body made three comments related to a portion of the cleaning validation for industrial scale manufacturing, of which only one requires additional unplanned activity. ViroPharma does not expect this activity to take much time to complete.

The FDA also said that it has not finished reviewing the company's January 2012 updated responses in relation to the observations specific to the September 2011 inspection of the Amsterdam facility.

Cinryze is one of the leading products at ViroPharma. The company markets the drug worldwide in the intravenous form as a treatment for routine prophylaxis against angioedema attacks in adolescent and adult patients with hereditary angioedema ( HAE ).

ViroPharma undertook an expansion of the production capacity for Cinryze in 2009. In early 2010, the company submitted the Cinryze industrial scale manufacturing Prior Approval Supplement (PAS) to the FDA. In October 2010, the regulatory body issued a CRL, asking for additional information on observations from the pre-approval inspection and review of the technical processes. In October 2011, ViroPharma submitted its response to the CRL.

We currently have an Outperform recommendation on ViroPharma. The stock carries a Zacks #2 Rank (Buy rating) in the short-run.

VIROPHARMA ( VPHM ): Free Stock Analysis Report
To read this article on click here.
Zacks Investment Research

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: Investing , Business , Stocks
More Headlines for: CRL , HAE , VPHM

More from


Equity Research
Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by